NASDAQ:BCAB BioAtla (BCAB) Stock Price, News & Analysis $3.62 -0.25 (-6.46%) Closing price 04:00 PM EasternExtended Trading$3.53 -0.09 (-2.51%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About BioAtla Stock (NASDAQ:BCAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioAtla alerts:Sign Up Key Stats Today's Range$3.37▼$3.8250-Day Range$3.87▼$9.4652-Week Range$3.26▼$71.50Volume28,987 shsAverage Volume46,103 shsMarket Capitalization$6.01 millionP/E RatioN/ADividend YieldN/APrice Target$200.00Consensus RatingHold Company Overview BioAtla, Inc. (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity. Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials. Lead programs include BA3011, a conditionally active antibody targeting cMet for solid tumors, and BA3071, a conditionally active T-cell–engaging bispecific targeting prostate‐specific membrane antigen (PSMA) in metastatic castration-resistant prostate cancer. The company’s research pipeline also features several discovery‐stage CAB molecules directed against tumor-associated antigens and immune checkpoints, reflecting its strategy to address high‐unmet‐need indications. BioAtla serves a global patient population through internal research and development operations in the United States and China. The company’s R&D infrastructure integrates molecular engineering, translational biology and preclinical pharmacology, enabling rapid optimization of CAB candidates. In addition to its internal programs, BioAtla has entered into strategic collaborations and licensing agreements to accelerate development and broaden the therapeutic reach of its platform. Led by President and Chief Executive Officer Christian S. Neal, BioAtla’s management team brings extensive experience in antibody engineering, clinical development and regulatory affairs. The company’s mission is to transform the safety and efficacy profile of biologic therapies by harnessing the precision of conditionally active molecules. As BioAtla advances its clinical portfolio, it aims to deliver innovative treatment options that improve patient outcomes and set new standards in targeted oncology therapy.AI Generated. May Contain Errors. Read More BioAtla Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreBCAB MarketRank™: BioAtla scored higher than 40% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingBioAtla has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialBioAtla has a consensus price target of $200.00, representing about 5,292.3% upside from its current price of $3.71.Amount of Analyst CoverageBioAtla has received no research coverage in the past 90 days.Read more about BioAtla's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of BioAtla is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioAtla is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BioAtla's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.07% of the float of BioAtla has been sold short.Short Interest Ratio / Days to CoverBioAtla has a short interest ratio ("days to cover") of 3.65, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioAtla has recently increased by 30.02%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioAtla does not currently pay a dividend.Dividend GrowthBioAtla does not have a long track record of dividend growth. News and Social Media3.8 / 5News SentimentN/A News SentimentBioAtla has a news sentiment score of 3.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for BioAtla this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for BCAB on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioAtla insiders have not sold or bought any company stock.Percentage Held by Insiders11.77% of the stock of BioAtla is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.23% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioAtla's insider trading history. Receive BCAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCAB Stock News HeadlinesBioAtla (BCAB) Expected to Announce Quarterly Earnings on TuesdayMay 10, 2026 | americanbankingnews.comBioAtla Announces Share ConsolidationMarch 31, 2026 | globenewswire.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.May 20 at 1:00 AM | Profits Run (Ad)BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsMarch 31, 2026 | globenewswire.comBioAtla, Inc. Initiates Strategic Review Process and Workforce Restructuring to Enhance Shareholder ValueMarch 2, 2026 | quiverquant.comQBioAtla Announces Formal Process to Evaluate Strategic Options to Monetize AssetsMarch 2, 2026 | globenewswire.comBioAtla Faces Nasdaq Trading Suspension and Potential DelistingFebruary 6, 2026 | tipranks.comBioAtla Inc.January 21, 2026 | barrons.comSee More Headlines BCAB Stock Analysis - Frequently Asked Questions How have BCAB shares performed this year? BioAtla's stock was trading at $28.3850 at the beginning of the year. Since then, BCAB stock has decreased by 86.9% and is now trading at $3.7090. How were BioAtla's earnings last quarter? BioAtla, Inc. (NASDAQ:BCAB) issued its earnings results on Friday, May, 15th. The company reported ($4.22) EPS for the quarter, beating the consensus estimate of ($10.00) by $5.78. When did BioAtla's stock split? BioAtla's stock reverse split on Monday, April 6th 2026.A 1-50 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, April 5th 2026. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did BioAtla IPO? BioAtla (BCAB) raised $168 million in an initial public offering on Wednesday, December 16th 2020. The company issued 10,500,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG served as the underwriters for the IPO. Who are BioAtla's major shareholders? BioAtla's top institutional investors include Renaissance Technologies LLC (30.81%) and ADAR1 Capital Management LLC (13.74%). Insiders that own company stock include Jay M Phd Short, Lawrence Steinman and Sylvia Mcbrinn. View institutional ownership trends. How do I buy shares of BioAtla? Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioAtla own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioAtla investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Visa (V). Company Calendar Last Earnings5/15/2026Today5/20/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 BCAB's financial health is in the Red zone, according to TradeSmith. BCAB has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCAB CIK1826892 Webwww.bioatla.com Phone858-558-0708FaxN/AEmployees60Year Founded2007Price Target and Rating Average Price Target for BioAtla$200.00 High Price Target$200.00 Low Price Target$200.00 Potential Upside/Downside+5,424.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($50.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.61 million Net MarginsN/A Pretax Margin-2,530.85% Return on EquityN/A Return on Assets-307.62% Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick Ratio0.37 Sales & Book Value Annual Sales$2 million Price / Sales3.00 Cash FlowN/A Price / Cash FlowN/A Book Value($22.52) per share Price / Book-0.16Miscellaneous Outstanding Shares1,660,000Free Float1,462,000Market Cap$6.01 million OptionableOptionable Beta0.81 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:BCAB) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredFed story no one is tellingJ.P. Morgan's Private Bank quietly advised 333 billionaire families to move 60% of their portfolios into alter...TradeSmith | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThis same-day trade is getting a lot of attentionZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...Base Camp Trading | SponsoredThe sell discipline that changed my mind after 30 yearsPorter Stansberry spent 30 years ignoring outside investment systems - until he met Emmet Savage in Dublin. Sa...Porter & Company | SponsoredMemorial Day Event: Save 79% on Weiss Ratings Plus!Elon Musk calls it 'mind-blowing.' Fox News calls the scramble for it 'the new arms race.' Chris Graebe, Chief...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
